Secretive Agios Makes Splash with $33M Series A

This post was commissioned on July 7, 2008, and it was categorized as Uncategorized.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Image via Wikipedia

Agios Pharmaceuticals, backed by heavy hitters: Third Rock, Flagship and ARCH venture groups, announced it has closed a hefty, $33M Series A financing round.

There is very little substance in the press release or on the Agios website about the company or the technology.

The basic gist though, has to do with modulating the metabolism specific to cancer cells by preventing the hungry cells from breaking down glucose and other fuels.

$33M is a nice hall even for a Series B round so I’m sure there are some pretty hefty expectations at Agios this morning.

Theoretically Related Posts

November 17, 2008 -- Pacira Pharmaceuticals Raises $85 Million in Series A (2)
June 3, 2008 -- Funding Roundup: IRX, Genesis, Inimex, VeraLight and ONCODESIGN (0)
December 4, 2008 -- Catalyst Biosciences Raises $40 Million in Series C Financing (1)
November 17, 2008 -- Zafgen Raises $14 Million in Series B (0)
October 30, 2008 -- Alnara Pharmaceuticals, Inc. Secures $20 Million in Series A Round (0)
October 28, 2008 -- Lutonix Inc. Announces $20 Million Series B Financing (0)
September 8, 2008 -- Proteolix Raises $79M in Series C (0)
April 16, 2009 -- Lycera Closes $36 Million Series A (0)
April 15, 2009 -- Synageva Nets $30M (0)
February 24, 2009 -- Heptares Secures $30M in Series A Funding (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: